Drugs / QBECO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01809275 | Mar 2013 → Feb 2016 | Crohn disease | Qu Biologics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-02-10 | Qu Biologics Inc. | Results Qu Biologics’ Immunomodulator Clears Senescence qubiologics.com ↗
Qu’s QBECO immunomodulator substantially reduced the most widely used biomarker of cellular senescence in the liver of mice with fatty liver disease. |
| 2025-01-06 | Qu Biologics Inc. | Results Qu Biologics’ Immunomodulator Improves Fatty Liver Disease qubiologics.com ↗
In a series of studies at McMaster, Dr. Schertzer’s research group demonstrated that treatment with QBECO SSI resulted in a marked reduction in liver fat, inflammation, and fibrosis in fatty liver disease. |
| 2024-12-16 | Qu Biologics Inc. | Results Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor qubiologics.com ↗
In this experimental study, scientists demonstrated that combining QBECO SSI with CAR T-cell therapy significantly improved survival rates compared to CAR T-cell therapy alone, achieving an impressive 80% survival rate after 31 days of treatment. |
| 2021-07-13 | Qu Biologics Inc. | Results Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress qubiologics.com ↗
The RESTORE study, presented at ECCO 2021, demonstrated both symptom improvement/remission and endoscopic response. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-02-10 | Qu Biologics Inc. | Qu Biologics’ Immunomodulator Clears Senescence qubiologics.com ↗ |
| 2025-01-06 | Qu Biologics Inc. | Qu Biologics’ Immunomodulator Improves Fatty Liver Disease qubiologics.com ↗ |
| 2024-12-16 | Qu Biologics Inc. | Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor qubiologics.com ↗ |
| 2021-07-13 | Qu Biologics Inc. | Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress qubiologics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QBECO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01809275 ↗ |
| Action | Restore | “aims to restore rather than suppress immune function in CD” PMID 31380382 ↗ Jul 2019 |
| Modality | Other / unclassified | “a novel microbial-derived immunotherapy” PMID 31380382 ↗ Jul 2019 |
| Route | Subcutaneous | “administered subcutaneously” NCT01809275 ↗ |